Skip to main content
. 2016 Oct 19;66(1):25–32. doi: 10.1007/s00262-016-1913-7

Fig. 1.

Fig. 1

Blood glucose and c-peptide levels were measured throughout treatment with pembrolizumab, nab-paclitaxel, and carboplatin for adenocarcinoma of the lung. The data points represent 7-day intervals. Treatment was delayed several times for cytopenias, in addition to hyperglycemia after C2D1. C4D8 was held completely for cytopenias. C cycle, D day, P pembrolizumab, N nab-paclitaxel, R carboplatin, Anti-GAD anti-glutamic acid decarboxylase, Anti-IA2 anti-islet antigen 2